The American Association for Cancer Research (AACR) annual meeting is one of the largest gatherings of cancer researchers and oncologists in the world. The meeting is held 16-20 April in New Orleans. Biovica is attending the meeting to present a poster with new DiviTum™ results to demonstrate its use as a marker of efficacy for cell cycle regulating drugs and the ability to provide unique data for the impact on cell growth rate in a preclinical setting. Biovica aims to expand the collaboration and research network and to share the latest insights from on going clinical trials.

Mattias_Bergqvist

“At AACR we look forward to meet our research partners and to expand our collaborations with oncologists and pharmaceutical companies. The DiviTum™ data presented at the meeting demonstrates the potential of DiviTum™ to provide important information as a tool to evaluate efficacy of cell cycle regulating drugs in early development. Our ambition is to provide our partners access to the DiviTum™ technology to predict and evaluate drug efficacy for new cancer drugs so that patients can get the best possible treatment.” says Mattias Bergqvist, VP Marketing & Clinical Studies at Biovica.

MEET BIOVICA AT AACR

We look forward to discuss the latest results with DiviTum as a tool in preclinical & clinical development. If you wish to meet us at the AACR meeting please do not hesitate to contact us at bd@biovica.com.

Read more about AACR